TABLE 2
FROM:
Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults
H Narimatsu, S Terakura, K Matsuo, T Oba, T Uchida, H Iida, M Hamaguchi, M Watanabe, A Kohno, M Murata, M Sawa, K Miyamura and Y Morishita for the Nagoya Blood and Marrow Transplantation Group (NBMTG)
BACK TO ARTICLETable 2. Clinical impact of short-term MTX
| Variables | Patients with MTX | Patients without MTX | P-value |
|---|---|---|---|
| Number of patients | 40a | 37b | |
| Age (years): median (range) | 38 (18|[ndash]|66) | 52 (27|[ndash]|69) | <0.0001 |
| Risk of underlying disease (high|[sol]|low) | 23|[sol]|17 | 28|[sol]|9 | 0.15 |
| Preparative regimens (myeloablative|[sol]|reduced-intensity) | 21|[sol]|19 | 10|[sol]|27 | 0.036 |
| HLA matching | |||
| |[emsp]|6|[sol]|6 | 3 | 5 | 0.045 |
| |[emsp]|5|[sol]|6 | 15 | 22 | |
| |[emsp]|4|[sol]|6 | 22 | 10 | |
| Blood-type mismatch (match|[sol]|mismatch) | 12|[sol]|28 | 9|[sol]|28 | 0.62 |
| Previous transplantc | 5 | 9 | 0.24 |
| Cumulative incidence of neutrophil engraftment at day 100 (95|[percnt]| CI) | 70|[percnt]| (95|[percnt]| CI, 56|[ndash]|85|[percnt]|) | 72|[percnt]| (95|[percnt]| CI, 57|[ndash]|87|[percnt]|) | 0.33 |
| Cumulative incidence of PIR at day 30 | 25|[percnt]| (95|[percnt]| CI, 11|[ndash]|39|[percnt]|) | 49|[percnt]| (95|[percnt]| CI, 32|[ndash]|65|[percnt]|) | 0.015 |
| Cumulative incidence of ES at day 60 | 10|[percnt]| (95|[percnt]| CI, 1|[ndash]|19|[percnt]|) | 14|[percnt]| (95|[percnt]| CI, 2|[ndash]|25|[percnt]|) | 0.65 |
| Cumulative incidence of grade II|[ndash]|IV acute GVHD at day 100 | 17|[percnt]| (95|[percnt]| CI, 4.2|[ndash]|29|[percnt]|) | 28|[percnt]| (95|[percnt]| CI, 11|[ndash]|44|[percnt]|) | 0.37 |
| Cumulative incidence of post-CBT immune reactionsd at day 100 | 48|[percnt]| (95|[percnt]| CI, 32|[ndash]|63|[percnt]|) | 65|[percnt]| (95|[percnt]| CI, 49|[ndash]|81|[percnt]|) | 0.042 |
| Cumulative incidence of relapse or progression of underlying diseases at day 100 | 10|[percnt]| (95|[percnt]| CI, 1|[ndash]|19|[percnt]|) | 22|[percnt]| (95|[percnt]| CI, 8|[ndash]|35|[percnt]|) | 0.20 |
| Cumulative incidence of non-relapse mortality at day 100 | 52|[percnt]| (95|[percnt]| CI, 32|[ndash]|72|[percnt]|) | 53|[percnt]| (95|[percnt]| CI, 36|[ndash]|69|[percnt]|) | 0.97 |
| Patients who developed documented infection | 19 | 18 |
Abbreviations: CBT|[equals]|cord blood transplantation; CI|[equals]|confidence interval; ES|[equals]|engraftment syndrome; GVHD|[equals]|graft-versus-host disease; HLA|[equals]|human leukocyte antigen; MTX|[equals]|methotrexate; PIR|[equals]|pre-engraftment immune reaction.
a Those included cyclosporine|[plus]|MTX (n|[equals]|17) and tacrolimus|[plus]|MTX (n|[equals]|23).
b Those included cyclosporine alone (n|[equals]|23) and tacrolimus alone (n|[equals]|12) and tacrolimus|[plus]|methylprednisolone (n|[equals]|2).
c Previous transplant included autologous and allogeneic hematopoietic stem cell transplantation.
d Those included PIR, ES and grade II|[ndash]|IV acute GVHD.
